TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06424652

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draws
Description: After passing the screening, participation in the research study will be approximately three weeks. The participant will have seven study visits all at the Pennington Center. On five occasions, the participant will have a five-hour visit in the inpatient unit. At the study visit blood will be drawn. The total amount of blood drawn during the study is approximately 12 fluid ounces.

Intervention type: OTHER
Group type: OTHER
Intervention: Hyperinsulinemic Euglycemic Clamp Technique Insulin Sensitivity test
Description: This procedure measures how the body responds to insulin. Insulin is normally produced by the body during meals and helps the body use sugar. There will be two IV lines, one in the participant's arm and one in the participant's hand on the opposite side. Small amounts of glucose and insulin will be infused into the participant's arm. The participant's blood sugar level will be checked every 5-10 minutes from the IV in the hand to determine how much glucose the participant should have to keep blood sugar at a normal level. The participant's hand will be placed inside a warming box to increase skin temperature to about 105 degrees Fahrenheit. The temperature will be warm, but not uncomfortable. During the IV procedure, a small amount of the participant's own blood (less than 1 teaspoon) will immediately be returned into the vein through the IV after each specimen is collected.

Intervention type: OTHER
Group type: OTHER
Intervention: Resting Metabolic Rate (RMR)
Description: After the participant rests for 30 minutes, a clear plastic hood will be placed over the participant's head and chest area. The hood is ventilated with fresh air. The participant's oxygen intake and carbon dioxide output will be measured for 30 minutes to determine how many calories the participant burns during the time they are being tested.
Study: NCT06265662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Digital Health Program for Non-Communicable Disease Prevention in a Workplace Setting in Thailand
Description: The program consists of two main components: (1) Participants are invited to join health courses and/or health activities in the form of seminars or group activities, and (2) Participants will have access to an application that is part of the program, where they can consult with health experts to plan lifestyle modifications and reduce behavioral risk factors over the 6-month duration of the research project, totaling four sessions, each lasting one hour.
Study: NCT05834829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity focused ultrasound neuromodulation
Description: ultrasound transducer applying low intensity waveforms to targeted brain regions for neuromodulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity focused ultrasound neuromodulation
Description: ultrasound transducer applying low intensity waveforms to targeted brain regions for neuromodulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Low-intensity focused ultrasound
Description: sham application of ultrasound using blocking of the ultrasound waves of the transducer.
Study: NCT05404932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliquoted allogeneic donor plasma in patient's conjunctiva
Description: 1-2 drops of allogenic aliquoted plasma to affected eye every 1-5 hours per day based on disease severity to be weaned down based on clinical response Administration period: Two to Six months. This may be repeated based on recurrence/worsening of conjunctivitis
Study: NCT05835817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetoencephalography
Description: 40 minutes of Magnetoencephalography with Optical Pump Magnetometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetoencephalography
Description: 40 minutes of Magnetoencephalography with Optical Pump Magnetometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetoencephalography
Description: 40 minutes of Magnetoencephalography with Optical Pump Magnetometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetoencephalography
Description: 40 minutes of Magnetoencephalography with Optical Pump Magnetometer
Study: NCT06233266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor-Test product
Description: Ticagrelor Tablets 90 mg Manufactured by: Mankind Pharma Limited, India

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor-Reference product
Description: Ticagrelor Tablets 90 mg Manufactured by: AstraZeneca AB, Sweden
Study: NCT03567213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical implantation of CortiCom system
Description: Implantation of Cortical communication system, consisting of one or two Electrocorticography (ECoG) grids connected to a transcutaneous patient pedestal.
Study: NCT06148909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small Talk Motivational Interviewing
Description: Combining small talks and skills on Motivational Interviewing in the smoking cessation services
Study: NCT04826796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp peer support
Description: Trained peer supporters will provide breastfeeding and emotional support for participants in the WhatsApp group.
Study: NCT06028009

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of platelet-rich plasma
Description: Injection of autologous platelet-rich plasma into anterior vaginal wall

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Injection of saline
Description: Injection of sterile normal saline into anterior vaginal wall
Study: NCT04971096

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS23 live
Description: PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 30 billion CFU (colony forming units) of PS23

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS23 heat-treated
Description: The PS23 heat-treated probiotic capsule contain 30 billion of PS23 cells.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsule contains microcrystalline cellulose.
Study: NCT05861648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid Oral Tablet
Description: Dietary Supplement: Folic acid 2.5mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary Supplement: Placebo
Study: NCT06409962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technological combination
Description: The intervention comprises workshops, individualized counseling, cooking classes, and physical activity promotion. It emphasizes nutritional education, hands-on cooking, and behavioral modification techniques. Participants receive personalized guidance and resources to make sustainable dietary and lifestyle changes. Social support networks foster motivation and accountability. By combining these components, the intervention aims to empower participants with the knowledge, skills, and support needed for long-term health improvements.
Study: NCT06004102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reminder text message
Description: The study aimed to assess the impact of text message reminders on medication adherence among kidney transplant recipients.
Study: NCT06516419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concentrated secretome Injection 2mL
Description: The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by IPT RSCM Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: 1. Tranexamic acid 25 mg/ml is prepared by taking tranexamic acid in a vial 250 mg/5 ml as much as 0.5 ml (25 mg) using a 1 ml syringe and diluted with 0.5 ml 0.9% NaCl solution just before being injected into the SP.~2. Tranexamic acid 10 mg/ml is prepared by taking 0.2 ml (10 mg) of AT in a 250 mg/5 ml vial using a 1 ml syringe and diluting it with 0.8 ml of 0.9% NaCl solution for a moment. before injection into the Subject~2. Tranexamic acid 10 mg/ml is prepared by taking 0.2 ml (10 mg) of AT in a 250 mg/5 ml vial using a 1 ml syringe and diluting it with 0.9% normal saline (NS) 0.8 ml just before injection into the Subject

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Combination Cream
Description: 1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream (Refaquin) containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle.
Study: NCT06140810

Intervention type: OTHER
Intervention: Lung Recruitment
Description: Lung Recruitment will be performed during general anesthesia to reduce areas of atelectasis
Study: NCT06149468

Intervention type: OTHER
Intervention: inclusion in the register
Description: socio-demographic data collection and proposed therapy
Study: NCT04619771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
Study: NCT05083585

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF-based vaccine
Description: Ad26.RSV.preF-based vaccine will be administered as a single intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF-based vaccine
Description: Ad26.RSV.preF-based vaccine will be administered as a single intramuscular injection.
Study: NCT05226494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fb-PMT
Description: Daily dosing based on patient weight
Study: NCT06327880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07054894 or placebo
Description: multiple oral doses of PF-07054894 for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-07054894 or placebo
Description: multiple oral doses of PF-07054894 for 14 days
Study: NCT06254365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Exogenous LEAP2 hormone
Description: This intervention has never been examined in this type of study before.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Exogenous LEAP2 hormone
Description: This intervention has never been examined in this type of study before.
Study: NCT04858022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Acoustic Biofeedback
Description: In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment - waitlist
Description: 10-week period of no treatment
Study: NCT06522542

Intervention type: DRUG
Intervention: systematic therapy
Description: All patients received systematic therapy including chemotherapy, targeted therapy or immune checkpoint inhibitor. We aims to investigate the impact of bleeding on the survival and treatment-related adverse events (TRAEs) of gastric cancer patients.

Intervention type: DRUG
Intervention: systematic therapy
Description: All patients received systematic therapy including chemotherapy, targeted therapy or immune checkpoint inhibitor. We aims to investigate the impact of bleeding on the survival and treatment-related adverse events (TRAEs) of gastric cancer patients.
Study: NCT06314828

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RJMty19 (CD19-CAR-DNT cells)
Description: Lentiviral vector-transducted double negative T cells (DNT) to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide, fludarabine and Etoposide lymphodepleting chemotherapy.
Study: NCT06326333

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Combined parasternal block and serratus anterior plane block
Description: The first PSB will be applied to the patients with 7.5 ml of 0.25% bupivacaine under real-time ultrasound guidance at the level of the second intercostal space.~The second PSB will be applied to the patients with 7.5 ml of 0.25% bupivacaine under real-time ultrasound guidance at the level of the fourth intercostal space.~The SAPB will be applied to the patients with 10 ml of 0.25% bupivacaine under real-time ultrasound guidance at the level of the sixth rib in the anterior axillary line.~The block applications will be applied bilaterally.
Study: NCT05925868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness app
Description: Parents will use the mindfulness app, Headspace, for at least 10 minutes on 4 days/week.
Study: NCT06373133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-8068
Description: 1mg/kg，ivgtt, d1, q6w or 4mg/kg，ivgtt, d1, q12w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: 1200mg, ivgtt, d1, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP102
Description: 7.5mg/kg, ivgtt, d1, q3w
Study: NCT04240834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
Study: NCT04753151

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid
Description: The study will be designed as a prospective, double-blinded clinical trial, compared to placebo (0.9% saline) in combination with conventional treatment. Patients will receive intravenous administration of 10 mg / kg tranexamic acid or placebo (0.9% saline) for 10 minutes in the 20 minutes prior to the estimated skin incision. Right after the skin incision, a maintenance dose of 1 mg / kg / h of tranexamic acid (or equivalent infusion rate of 0.9% saline) will be started, remaining until the end of the suture of the surgical wound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: The study will be designed as a prospective, double-blinded clinical trial, compared to placebo (0.9% saline) in combination with conventional treatment. Patients will receive intravenous administration of 10 mg / kg tranexamic acid or placebo (0.9% saline) for 10 minutes in the 20 minutes prior to the estimated skin incision. Right after the skin incision, a maintenance dose of 1 mg / kg / h of tranexamic acid (or equivalent infusion rate of 0.9% saline) will be started, remaining until the end of the suture of the surgical wound.
Study: NCT02406534

Intervention type: BEHAVIORAL
Intervention: HRQoL surveys

Intervention type: BEHAVIORAL
Intervention: HRQoL surveys
Study: NCT06443567

Intervention type: DEVICE
Intervention: impedance threshold device
Description: impedance threshold device (ResQPOD, Zoll) applied to airway
Study: NCT05386407

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: telemedically guided oropharyngeal + nasal (OP+N) self-sampling (GSS) and nasopharyngeal (NP) or OP+N sampling performed by health care professionals (HCP)
Description: After giving informed consent by signing the consent form, patients will be randomized to either OP+N GSS - or to OP+N USS.~After performing either procedure, they will continue to be sampled by HCP OP+N and HCP NP.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: telemedically guided oropharyngeal + nasal (OP+N) self-sampling (GSS) and nasopharyngeal (NP) or OP+N sampling performed by health care professionals (HCP)
Description: After giving informed consent by signing the consent form, patients will be randomized to either OP+N GSS - or to OP+N USS.~After performing either procedure, they will continue to be sampled by HCP OP+N and HCP NP.
Study: NCT06307197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HAAL platform
Description: The HAAL platform is composed by 6 devices (lifestyle monitoring system, a smart mattress, a GPS tracking system, a social robot, an interactive game for cognitive training, and an alarm system), 1 tablet and 1 dashboard. Each user benefits of a combination of such devices, according to its own needs. The dashboard, that is used by the Formal Caregiver, receives, analyses, and show data acquired by those devices.~The platform uses Artificial Intelligence (AI) algorithms - in particular machine learning (ML) is used - to analyse the collected data. The main reason for using AI in HAAL is that the platform collects data from different sensors.
Study: NCT06329895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088
Description: Oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral administration.
Study: NCT05040503

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling at inclusion
Description: Sampling of 2 tubes of 3 ml:~* patient: H0: 0-6h post-admission~* healthy volunteer: at inclusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling at inclusion
Description: Sampling of 2 tubes of 3 ml:~* patient: H0: 0-6h post-admission~* healthy volunteer: at inclusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling at inclusion
Description: Sampling of 2 tubes of 3 ml:~* patient: H0: 0-6h post-admission~* healthy volunteer: at inclusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling at inclusion
Description: Sampling of 2 tubes of 3 ml:~* patient: H0: 0-6h post-admission~* healthy volunteer: at inclusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling at 24 hours
Description: Collection of 2 tubes of 3 ml (H24: 24-30h post-admission)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling at 24 hours
Description: Collection of 2 tubes of 3 ml (H24: 24-30h post-admission)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling at 24 hours
Description: Collection of 2 tubes of 3 ml (H24: 24-30h post-admission)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data collection
Description: clinical and biological medical data for patients and general health data for healthy volunteers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data collection
Description: clinical and biological medical data for patients and general health data for healthy volunteers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data collection
Description: clinical and biological medical data for patients and general health data for healthy volunteers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data collection
Description: clinical and biological medical data for patients and general health data for healthy volunteers
Study: NCT05679895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD1a-CAR T
Description: Autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express CD1a chimeric antigen receptor administered by intravenous infusion following a dose-escalation approach
Study: NCT05302336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide
Description: All patients who meet the inclusion criteria must first sign the Informed Consent after learning about the details of the trial, and they can be formally enrolled only when they have completed all the pre-enrollment examinations and are qualified. Recruitment will continue until the planned number of cases is completed. The trial was not terminated until each surviving patient was followed for at least 60 months after treatment ended or when all patients had died. The randomization table was generated by the SAS software program, and the patients were randomly divided into the experimental group (AC liposomal doxorubicin + cyclophosphamide) and the control group (docetaxel + cyclophosphamide).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide
Description: All patients who meet the inclusion criteria must first sign the Informed Consent after learning about the details of the trial, and they can be formally enrolled only when they have completed all the pre-enrollment examinations and are qualified. Recruitment will continue until the planned number of cases is completed. The trial was not terminated until each surviving patient was followed for at least 60 months after treatment ended or when all patients had died. The randomization table was generated by the SAS software program, and the patients were randomly divided into the experimental group (AC liposomal doxorubicin + cyclophosphamide) and the control group (docetaxel + cyclophosphamide).
Study: NCT04232293

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood tests
Description: eLift and FibroMeter
Study: NCT05225805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lefamulin
Description: Antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lefamulin
Description: Antibiotic
Study: NCT04947982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: carbon dioxide
Description: carbon dioxide insufflation pressure